Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial

<p>Abstract</p> <p>Background</p> <p>Gestational hypertension (GH) and pre-eclampsia (PE) can result in severe complications such as eclampsia, placental abruption, syndrome of Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) and ultimately even neonatal or m...

Full description

Saved in:
Bibliographic Details
Main Authors: Sporken Jan M J (Author), Perquin Denise A M (Author), Franssen Maureen T M (Author), Wijnen-Duvekot Ella J (Author), Willekes Christine (Author), Oosterbaan Herman P (Author), van Huizen Marloes E (Author), van Beek Erik (Author), Groot Christianne (Author), Bloemenkamp Kitty W (Author), Oudijk Martijn A (Author), Porath Martina (Author), Groen Henk (Author), van Kaam Anton H (Author), van Pampus Maria G (Author), van Baaren Gert-Jan (Author), Broekhuijsen Kim (Author), Langenveld Josje (Author), Woiski Mallory D (Author), Bremer Henk A (Author), Papatsonis Dimitri N M (Author), Brons Jozien T J (Author), Kaplan Mesruwe (Author), Nij Bijvanck Bas W A (Author), Mol Ben-Willen J (Author)
Format: Book
Published: BMC, 2011-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b067b51e7f45425db8e5d4420f2d8d3e
042 |a dc 
100 1 0 |a Sporken Jan M J  |e author 
700 1 0 |a Perquin Denise A M  |e author 
700 1 0 |a Franssen Maureen T M  |e author 
700 1 0 |a Wijnen-Duvekot Ella J  |e author 
700 1 0 |a Willekes Christine  |e author 
700 1 0 |a Oosterbaan Herman P  |e author 
700 1 0 |a van Huizen Marloes E  |e author 
700 1 0 |a van Beek Erik  |e author 
700 1 0 |a Groot Christianne  |e author 
700 1 0 |a Bloemenkamp Kitty W  |e author 
700 1 0 |a Oudijk Martijn A  |e author 
700 1 0 |a Porath Martina  |e author 
700 1 0 |a Groen Henk  |e author 
700 1 0 |a van Kaam Anton H  |e author 
700 1 0 |a van Pampus Maria G  |e author 
700 1 0 |a van Baaren Gert-Jan  |e author 
700 1 0 |a Broekhuijsen Kim  |e author 
700 1 0 |a Langenveld Josje  |e author 
700 1 0 |a Woiski Mallory D  |e author 
700 1 0 |a Bremer Henk A  |e author 
700 1 0 |a Papatsonis Dimitri N M  |e author 
700 1 0 |a Brons Jozien T J  |e author 
700 1 0 |a Kaplan Mesruwe  |e author 
700 1 0 |a Nij Bijvanck Bas W A  |e author 
700 1 0 |a Mol Ben-Willen J  |e author 
245 0 0 |a Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial 
260 |b BMC,   |c 2011-07-01T00:00:00Z. 
500 |a 10.1186/1471-2393-11-50 
500 |a 1471-2393 
520 |a <p>Abstract</p> <p>Background</p> <p>Gestational hypertension (GH) and pre-eclampsia (PE) can result in severe complications such as eclampsia, placental abruption, syndrome of Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) and ultimately even neonatal or maternal death. We recently showed that in women with GH or mild PE at term induction of labour reduces both high risk situations for mothers as well as the caesarean section rate. In view of this knowledge, one can raise the question whether women with severe hypertension, pre-eclampsia or deterioration chronic hypertension between 34 and 37 weeks of gestation should be delivered or monitored expectantly. Induction of labour might prevent maternal complications. However, induction of labour in late pre-term pregnancy might increase neonatal morbidity and mortality compared with delivery at term.</p> <p>Methods/Design</p> <p>Pregnant women with severe gestational hypertension, mild pre-eclampsia or deteriorating chronic hypertension at a gestational age between 34<sup>+0 </sup>and 36<sup>+6 </sup>weeks will be asked to participate in a multi-centre randomised controlled trial. Women will be randomised to either induction of labour or expectant monitoring. In the expectant monitoring arm, women will be induced only when the maternal or fetal condition detoriates or at 37<sup>+0 </sup>weeks of gestation. The primary outcome measure is a composite endpoint of maternal mortality, severe maternal complications (eclampsia, HELLP syndrome, pulmonary oedema and thromboembolic disease) and progression to severe pre-eclampsia. Secondary outcomes measures are respiratory distress syndrome (RDS), neonatal morbidity and mortality, caesarean section and vaginal instrumental delivery rates, maternal quality of life and costs. Analysis will be intention to treat. The power calculation is based on an expectant reduction of the maternal composite endpoint from 5% to 1% for an expected increase in neonatal RDS from 1% at 37 weeks to 10% at 34 weeks. This implies that 680 women have to be randomised.</p> <p>Discussion</p> <p>This trial will provide insight as to whether in women with hypertensive disorders late pre-term, induction of labour is an effective treatment to prevent severe maternal complications without compromising the neonatal morbidity.</p> <p>Trial Registration</p> <p><a href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=NTR1792">NTR1792</a> Clinical trial registration: <url>http://www.trialregister.nl</url></p> 
546 |a EN 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n BMC Pregnancy and Childbirth, Vol 11, Iss 1, p 50 (2011) 
787 0 |n http://www.biomedcentral.com/1471-2393/11/50 
787 0 |n https://doaj.org/toc/1471-2393 
856 4 1 |u https://doaj.org/article/b067b51e7f45425db8e5d4420f2d8d3e  |z Connect to this object online.